Nanotechnol Sci Appl. 2010 Jun 17;3:29-35. doi: 10.2147/nsa.s9591. eCollection 2010.

Evaluation of antidiphtheria toxin nanobodies.

Nanotechnology, science and applications

Ghada H Shaker

PMID: 24198468 PMCID: PMC3781745 DOI: 10.2147/nsa.s9591

Abstract

Nanobodies are the smallest fragments of naturally occurring single-domain antibodies that have evolved to be fully functional in the absence of a light chain. Conventional antibodies are glycoproteins comprising two heavy and two light chains. Surprisingly, all members of the Camelidae family possess a fraction of antibodies devoid of both light chains and the first constant domain. These types of antibodies are known as heavy-chain antibody (HcAb) nanobodies. There are three subclasses of IgG in dromedaries, namely IgG1, IgG2, and IgG3 of which IgG2 and IgG3 are of the HcAb type. These heavy chain antibodies constitute approximately 50% of the IgG in llama serum and as much as 75% of the IgG in camel serum. In the present work, the different IgG subclasses from an immunized camel (Camelus dromedarius) with divalent diphtheria-tetanus vaccine were purified using their different affinity for protein A and protein G and their absorbance measured at 280 nm. Purity control and characterization by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis of IgG subclasses was done under reducing conditions. Protein bands were visualized after staining with Coomassie Blue, showing two bands at 50 kDa and 30 kDa for IgG1, while IgG2 and IgG3 produced only one band at 46 kDa and 43 kDa, respectively. An enzyme-linked immunosorbent assay test using diphtheria toxin and purified IgG subclasses from the immunized camel were performed to evaluate their efficiency. Compared with conventional IgG1, heavy chain antibodies (nanobodies) were shown to be more efficient in binding to diphtheria toxin antigen. This study revealed the possibility of using IgG2 and IgG3 nanobodies as an effective antitoxin for the treatment of diphtheria in humans.

Keywords: HcAb; IgG subclasses; camel; diphtheria toxin; heavy chain antibody; immunoglobulin; nanobodies

References

1. Clin Diagn Lab Immunol. 2005 Mar;12(3):380-6 - PubMed
2. Bacteriol Rev. 1970 Dec;34(4):378-422 - PubMed
3. Nature. 1970 Aug 15;227(5259):680-5 - PubMed
4. Structure. 1999 Apr 15;7(4):361-70 - PubMed
5. J Biol Chem. 2001 Mar 9;276(10):7346-50 - PubMed
6. J Biol Chem. 1971 Mar 10;246(5):1485-91 - PubMed
7. Vet Immunol Immunopathol. 2007 Jun 15;117(3-4):173-82 - PubMed
8. Vet Immunol Immunopathol. 2001 Nov;83(1-2):1-9 - PubMed
9. Acta Pathol Microbiol Immunol Scand C. 1986 Oct;94(5):219-25 - PubMed
10. Vaccine. 2006 May 8;24(19):4130-7 - PubMed
11. MMWR Recomm Rep. 2002 Feb 8;51(RR-2):1-35 - PubMed
12. Anal Chem. 2006 Jul 1;78(13):4501-8 - PubMed
13. Biosens Bioelectron. 2005 Sep 15;21(3):483-90 - PubMed
14. Nature. 1993 Jun 3;363(6428):446-8 - PubMed
15. Vet Immunol Immunopathol. 2008 Nov 15;126(1-2):64-73 - PubMed
16. J Immunol Methods. 2000 Jun 23;240(1-2):185-95 - PubMed
17. J Immunol Methods. 2005 Jan;296(1-2):159-70 - PubMed
18. Protein Sci. 2002 Mar;11(3):500-15 - PubMed
19. Dev Comp Immunol. 2003 Feb;27(2):87-103 - PubMed
20. J Bacteriol. 1971 Jan;105(1):77-85 - PubMed
21. Antimicrob Agents Chemother. 2001 Oct;45(10):2807-12 - PubMed
22. J Infect Dis. 2000 Feb;181 Suppl 1:S10-22 - PubMed
23. J Immunol Methods. 2007 Jul 31;324(1-2):13-25 - PubMed
24. Anal Chem. 2006 Dec 15;78(24):8245-55 - PubMed
25. Scand J Infect Dis. 1988;20(2):177-85 - PubMed
26. Protein Eng. 1994 Sep;7(9):1129-35 - PubMed
27. J Biol Chem. 2004 Jan 9;279(2):1256-61 - PubMed
28. J Biotechnol. 2000 Feb 28;78(1):11-21 - PubMed
29. FEBS Lett. 1997 Sep 15;414(3):521-6 - PubMed
30. J Infect Dis. 2007 Nov 15;196 Suppl 2:S213-9 - PubMed

Publication Types

• Journal Article